| abstract |
The present invention provides monoclonal antibodies that bind to the Middle East respiratory syndrome-coronavirus (MERS-CoV) spike protein, and methods of use thereof. In various embodiments of the invention, the antibody is a full-length human antibody that binds to the MERS-CoV spike protein. In some embodiments, the antibodies of the invention can be used to inhibit or neutralize MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in the treatment of MERS infection. In some embodiments, the one or more antibodies bind to distinct non-competitive epitopes contained in the receptor binding domain of the MERS-CoV spike protein. |